MedPath

A randomised, parallel group study on efficacy and tolerability of Escherichia coli rHu granulocyte-macrophage colony-stimulating factor (GM-CSF) given subcutaneously for seven days after chemotherapy in paediatric malignancy

Not Applicable
Completed
Conditions
Chemotherapy in paediatric malignancy
Cancer
Malignancy
Registration Number
ISRCTN54672574
Lead Sponsor
nited Kingdom Children's Cancer Study Group (UK)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
0
Inclusion Criteria

1. Newly diagnosed soft tissue sarcoma, Ewing's sarcoma, medulloblastoma, osteosarcoma or Non-Hodgkin's Lymphoma
2. Age range 1 to 15 years
3. No history of anaphylaxis
4. No severe lung, heart or kidney impairment

Exclusion Criteria

Not provided at time of registration

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ot provided at time of registration
Secondary Outcome Measures
NameTimeMethod
ot provided at time of registration
© Copyright 2025. All Rights Reserved by MedPath